Business Description
TCM Biotech International Corp
ISIN : TW0004169008
Total Employee Number:
106Description
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 24.3 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 2.08 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 40.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.8 | |||||
3-Year EBITDA Growth Rate | -5.2 | |||||
3-Year EPS without NRI Growth Rate | -6.3 | |||||
3-Year FCF Growth Rate | -15.3 | |||||
3-Year Book Growth Rate | 14.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 13.07 | |||||
9-Day RSI | 23.55 | |||||
14-Day RSI | 31.75 | |||||
3-1 Month Momentum % | 75.16 | |||||
6-1 Month Momentum % | 46.45 | |||||
12-1 Month Momentum % | 195.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.49 | |||||
Quick Ratio | 5.39 | |||||
Cash Ratio | 4.14 | |||||
Days Inventory | 133.86 | |||||
Days Sales Outstanding | 68.97 | |||||
Days Payable | 38.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.2 | |||||
Forward Dividend Yield % | 0.2 | |||||
5-Year Yield-on-Cost % | 0.2 | |||||
3-Year Average Share Buyback Ratio | -9.1 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.26 | |||||
Operating Margin % | -2.43 | |||||
Net Margin % | -1.96 | |||||
EBITDA Margin % | 1.67 | |||||
FCF Margin % | 3.76 | |||||
OCF Margin % | 4.11 | |||||
ROE % | -1.29 | |||||
ROA % | -1.13 | |||||
ROIC % | -2.95 | |||||
3-Year ROIIC % | 9.01 | |||||
ROC (Joel Greenblatt) % | -2.38 | |||||
ROCE % | -1.03 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 367.59 | |||||
Price-to-Owner-Earnings | 7850 | |||||
PS Ratio | 13.12 | |||||
PB Ratio | 9.4 | |||||
Price-to-Tangible-Book | 9.54 | |||||
Price-to-Free-Cash-Flow | 354.4 | |||||
Price-to-Operating-Cash-Flow | 323.71 | |||||
EV-to-EBIT | -869.4 | |||||
EV-to-EBITDA | 842.01 | |||||
EV-to-Revenue | 14.03 | |||||
EV-to-FCF | 372.59 | |||||
Price-to-GF-Value | 3.71 | |||||
Price-to-Projected-FCF | 9.86 | |||||
| Price-to-Net-Current-Asset-Value | 13.56 | |||||
| Price-to-Net-Cash | 24.12 | |||||
Earnings Yield (Greenblatt) % | -0.12 | |||||
FCF Yield % | 0.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TCM Biotech International Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 703.089 | ||
| EPS (TTM) (NT$) | -0.24 | ||
| Beta | 0.082 | ||
| 3-Year Sharpe Ratio | 0.84 | ||
| 3-Year Sortino Ratio | 2.04 | ||
| Volatility % | 73.09 | ||
| 14-Day RSI | 31.75 | ||
| 14-Day ATR (NT$) | 14.239426 | ||
| 20-Day SMA (NT$) | 216.075 | ||
| 12-1 Month Momentum % | 195.48 | ||
| 52-Week Range (NT$) | 82.1 - 290 | ||
| Shares Outstanding (Mil) | 66.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TCM Biotech International Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TCM Biotech International Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 0.319991 Cash Dividend | 2026-07-20 | 252.00 (-2.89%) | ||
| TWD 0.350000 Cash Dividend | 2025-08-28 | 99.30 (+0.30%) | ||
| TWD 0.285000 Cash Dividend | 2024-08-28 | 56.80 (+0.35%) | ||
| 1.0306:1 Stock Split | 2023-07-20 | 62.55 (-1.90%) | ||
| 1.0288:1 Stock Split | 2014-08-25 | 46.01 (+0.00%) |
Show
Entries
TCM Biotech International Corp Frequently Asked Questions
What is TCM Biotech International Corp(TPE:4169)'s stock price today?
The current price of TPE:4169 is NT$157.00. The 52 week high of TPE:4169 is NT$290.00 and 52 week low is NT$82.10.
When is next earnings date of TCM Biotech International Corp(TPE:4169)?
The next earnings date of TCM Biotech International Corp(TPE:4169) is .
Does TCM Biotech International Corp(TPE:4169) pay dividends? If so, how much?
The Dividend Yield %  of TCM Biotech International Corp(TPE:4169) is 0.2% (As of Today), Highest Dividend Payout Ratio of TCM Biotech International Corp(TPE:4169) was 9.05. The lowest was 0.1. And the median was 0.81. The  Forward Dividend Yield % of TCM Biotech International Corp(TPE:4169) is 0.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| FDA Breakthrough for First Viral-Integration MRD Liquid Biopsy in HCC -- New ctDNA Biomarker Class | 2026-04-21 |
Articles on TCM Biotech International Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers